{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:03:41Z","timestamp":1781921021294,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100635","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:57:50Z","timestamp":1663246670000},"page":"100635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study"],"prefix":"10.1016","volume":"33","author":[{"given":"Samya","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumi","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahena","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debmalya","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha Pratim","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasweta","family":"Acharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanta","family":"Roychoudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-1218","authenticated-orcid":false,"given":"Somsubhra","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100635_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111584","article-title":"Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer","volume":"139","author":"Singh","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100635_bib0002","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"56","key":"10.1016\/j.ctarc.2022.100635_bib0003","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1038\/sj.onc.1205017","article-title":"Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase","volume":"20","author":"Dorey","year":"2001","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100635_bib0004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"15","key":"10.1016\/j.ctarc.2022.100635_bib0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100635_bib0006","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100635_bib0007","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic myeloid leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100635_bib0008","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2022.100635_bib0009","series-title":"Cytostatic Therapy of Chronic Myelogenous Leukemia: Review and Perspectives","year":"1988"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100635_bib0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/2278-330X.187593","article-title":"Summary of the published Indian data on chronic myeloid leukemia","volume":"5","author":"Singhal","year":"2016","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100635_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.06.026","article-title":"Long-term outcome of philadelphia chromosome positive leukemia from eastern indian subcontinent: an experience in the era of tyrosine kinase inhibitor (TKI) therapy","author":"Dey","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.ctarc.2022.100635_bib0012","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100635_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2011.02.001","article-title":"Interpretation of cytogenetic and molecular results in patients treated for CML","volume":"25","author":"Vigil","year":"2011","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100635_bib0014","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0971-5851.123748","article-title":"Imatinib mesylate resistance and mutations: an Indian experience","volume":"34","author":"Srivastava","year":"2013","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100635_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ctarc.2022.100635_bib0016","series-title":"Practical Surgical Neuropathology: A Diagnostic Approach","first-page":"71","article-title":"5 - integrating molecular diagnostics with surgical neuropathology","author":"Solomon","year":"2018"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100635_bib0017","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2022.100635_bib0018","unstructured":"Andrews S. FastQC: a quality control tool for high throughput sequence data [Online]. 2010."},{"key":"10.1016\/j.ctarc.2022.100635_bib0019","unstructured":"F.K. Trimgalore (2021), GitHub repository, 2021 [Available from: https:\/\/github.com\/FelixKrueger\/TrimGalore."},{"issue":"14","key":"10.1016\/j.ctarc.2022.100635_bib0020","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with burrows-wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"16","key":"10.1016\/j.ctarc.2022.100635_bib0021","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"8","key":"10.1016\/j.ctarc.2022.100635_bib0022","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/bioinformatics\/bts091","article-title":"Unipro UGENE: a unified bioinformatics toolkit","volume":"28","author":"Okonechnikov","year":"2012","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100635_bib0023","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100635_bib0024","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ctarc.2022.100635_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3906\/biy-1405-21","article-title":"Multidrug resistance in chronic myeloid leukemia","volume":"38","author":"\u00dcNl\u00dc","year":"2014","journal-title":"Turkish J. Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100635_bib0026","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41598-019-38672-x","article-title":"Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients","volume":"9","author":"Chandrasekhar","year":"2019","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.ctarc.2022.100635_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25184210","article-title":"Bcr-Abl allosteric inhibitors: where we are and where we are going to","volume":"25","author":"Carofiglio","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100635_bib0028","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/gtmb.2012.0272","article-title":"BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients","volume":"17","author":"McCarron","year":"2013","journal-title":"Genet Test Mol. Biomarkers"},{"issue":"10","key":"10.1016\/j.ctarc.2022.100635_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.06.031","article-title":"Comparison of frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and white patients With Imatinib-resistant chronic-phase chronic myeloid leukemia","volume":"18","author":"Kim","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2022.100635_bib0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/GO.21.00058","article-title":"Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian Imatinib-resistant patients with chronic myeloid leukemia","volume":"7","author":"Tadesse","year":"2021","journal-title":"JCO Glob. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100635_bib0031","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100635_bib0032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12288-018-01068-4","article-title":"Applications of next generation sequencing in haematological disorders-Indian status: updates from ISHBT 2018","volume":"35","author":"Maddali","year":"2019","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100635_bib0033","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1080\/10428194.2021.1872074","article-title":"BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib","volume":"62","author":"Benjamin","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100635_bib0034","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic myeloid leukemia: mechanisms of resistance and treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"8","key":"10.1016\/j.ctarc.2022.100635_bib0035","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.ctarc.2022.100635_bib0036","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.18632\/oncotarget.27652","article-title":"Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib","volume":"11","author":"Genthon","year":"2020","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100635_bib0037","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1179\/1607845412Y.0000000050","article-title":"Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance","volume":"18","author":"Chahardouli","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.ctarc.2022.100635_bib0038","article-title":"The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia","volume":"2012","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk. Res. Treatment"},{"issue":"11","key":"10.1016\/j.ctarc.2022.100635_bib0039","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1038\/s41375-020-01037-9","article-title":"Declaration of Bcr-Abl1 independence","volume":"34","author":"Zhao","year":"2020","journal-title":"Leukemia"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:54Z","timestamp":1762842954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":39,"alternative-id":["S2468294222001265"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100635","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100635"}}